Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study
Background: Small intestine adenocarcinoma is a rare cancer. The current study aims to determine the outcomes of patients with small intestine adenocarcinoma in a Canadian province. Methods: This retrospective population-based cohort study assessed patients with small intestine adenocarcinoma who we...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/11/2581 |
| _version_ | 1797493997001768960 |
|---|---|
| author | Emma Yanko Duc Le Shazia Mahmood David Nathan Ginther Haji Ibraheem Chalchal Rani Kanthan Kamal Haider Adnan Zaidi Dorie-Anna Dueck Osama Ahmed Branawan Gowrishankar Shahid Ahmed |
| author_facet | Emma Yanko Duc Le Shazia Mahmood David Nathan Ginther Haji Ibraheem Chalchal Rani Kanthan Kamal Haider Adnan Zaidi Dorie-Anna Dueck Osama Ahmed Branawan Gowrishankar Shahid Ahmed |
| author_sort | Emma Yanko |
| collection | DOAJ |
| description | Background: Small intestine adenocarcinoma is a rare cancer. The current study aims to determine the outcomes of patients with small intestine adenocarcinoma in a Canadian province. Methods: This retrospective population-based cohort study assessed patients with small intestine adenocarcinoma who were diagnosed from 2008 to 2017 in Saskatchewan. A Cox proportional multivariate regression analysis was performed to determine the correlation between survival and exploratory factors. Results: 112 eligible patients with a median age of 73 years and M:F of 47:53 were identified. Overall, 75% had a comorbid illness, and 45% had a WHO performance status >1. Of the 112 patients, 51 (46%) had early-stage disease and 61 (54%) had advanced-stage disease. The median overall survival (mOS) was as follows: stage one, 59 months; stage two, 30 months; stage three, 20 months; and stage four, 3 months (<i>p</i> < 0.001). The median disease-free survival of patients with stage three disease who received adjuvant chemotherapy was 26 months (95% CI:23.1–28.9) vs. 4 months (0.0–9.1) with observation (<i>p</i> = 0.04). Patients who received chemotherapy for advanced disease had a mOS of 10 months (3.5–16.5) vs. 2 months (0.45–3.6) without chemotherapy (<i>p</i> < 0.001). In the multivariate analysis, stage four disease, hazard ratio (HR), 3.20 (1.84–5.40); WHO performance status >1, HR, 2.22 (1.42–3.45); lack of surgery, HR, 2.10 (1.25–3.50); and a neutrophil:lymphocyte ratio of >4.5, HR, 1.72 (1.10–2.71) were significantly correlated with inferior survival. Conclusions: Most patients with small intestine adenocarcinoma were diagnosed with advanced-stage disease. Advanced-stage disease, poor performance status, lack of surgery and a baseline neutrophil:lymphocyte ratio >4.5 were correlated with inferior survival. |
| first_indexed | 2024-03-10T01:27:57Z |
| format | Article |
| id | doaj.art-9f8799a6c506450098c18ac613d26d11 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:27:57Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9f8799a6c506450098c18ac613d26d112023-11-23T13:47:39ZengMDPI AGCancers2072-66942022-05-011411258110.3390/cancers14112581Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort StudyEmma Yanko0Duc Le1Shazia Mahmood2David Nathan Ginther3Haji Ibraheem Chalchal4Rani Kanthan5Kamal Haider6Adnan Zaidi7Dorie-Anna Dueck8Osama Ahmed9Branawan Gowrishankar10Shahid Ahmed11College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, CanadaBackground: Small intestine adenocarcinoma is a rare cancer. The current study aims to determine the outcomes of patients with small intestine adenocarcinoma in a Canadian province. Methods: This retrospective population-based cohort study assessed patients with small intestine adenocarcinoma who were diagnosed from 2008 to 2017 in Saskatchewan. A Cox proportional multivariate regression analysis was performed to determine the correlation between survival and exploratory factors. Results: 112 eligible patients with a median age of 73 years and M:F of 47:53 were identified. Overall, 75% had a comorbid illness, and 45% had a WHO performance status >1. Of the 112 patients, 51 (46%) had early-stage disease and 61 (54%) had advanced-stage disease. The median overall survival (mOS) was as follows: stage one, 59 months; stage two, 30 months; stage three, 20 months; and stage four, 3 months (<i>p</i> < 0.001). The median disease-free survival of patients with stage three disease who received adjuvant chemotherapy was 26 months (95% CI:23.1–28.9) vs. 4 months (0.0–9.1) with observation (<i>p</i> = 0.04). Patients who received chemotherapy for advanced disease had a mOS of 10 months (3.5–16.5) vs. 2 months (0.45–3.6) without chemotherapy (<i>p</i> < 0.001). In the multivariate analysis, stage four disease, hazard ratio (HR), 3.20 (1.84–5.40); WHO performance status >1, HR, 2.22 (1.42–3.45); lack of surgery, HR, 2.10 (1.25–3.50); and a neutrophil:lymphocyte ratio of >4.5, HR, 1.72 (1.10–2.71) were significantly correlated with inferior survival. Conclusions: Most patients with small intestine adenocarcinoma were diagnosed with advanced-stage disease. Advanced-stage disease, poor performance status, lack of surgery and a baseline neutrophil:lymphocyte ratio >4.5 were correlated with inferior survival.https://www.mdpi.com/2072-6694/14/11/2581small intestine adenocarcinomasmall intestine canceroutcomessurvivalsurgeryneutrophil lymphocyte ratio |
| spellingShingle | Emma Yanko Duc Le Shazia Mahmood David Nathan Ginther Haji Ibraheem Chalchal Rani Kanthan Kamal Haider Adnan Zaidi Dorie-Anna Dueck Osama Ahmed Branawan Gowrishankar Shahid Ahmed Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study Cancers small intestine adenocarcinoma small intestine cancer outcomes survival surgery neutrophil lymphocyte ratio |
| title | Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study |
| title_full | Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study |
| title_fullStr | Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study |
| title_full_unstemmed | Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study |
| title_short | Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study |
| title_sort | outcomes of patients with small intestine adenocarcinoma in a canadian province a retrospective multi center population based cohort study |
| topic | small intestine adenocarcinoma small intestine cancer outcomes survival surgery neutrophil lymphocyte ratio |
| url | https://www.mdpi.com/2072-6694/14/11/2581 |
| work_keys_str_mv | AT emmayanko outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT ducle outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT shaziamahmood outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT davidnathanginther outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT hajiibraheemchalchal outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT ranikanthan outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT kamalhaider outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT adnanzaidi outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT dorieannadueck outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT osamaahmed outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT branawangowrishankar outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy AT shahidahmed outcomesofpatientswithsmallintestineadenocarcinomainacanadianprovincearetrospectivemulticenterpopulationbasedcohortstudy |